Literature DB >> 25146548

μ-Opioid receptor attenuates Aβ oligomers-induced neurotoxicity through mTOR signaling.

Yan Wang1, Yan-Xia Wang, Ting Liu, Ping-Yee Law, Horace H Loh, Yu Qiu, Hong-Zhuan Chen.   

Abstract

AIMS: μ-opioid receptor (OPRM1) exerts many functions such as antinociception, neuroprotection, and hippocampal plasticity. A body of evidence has shown that OPRM1 activation could stimulate downstream effectors of mechanistic/mammalian target of rapamycin (mTOR). However, it is not clear whether OPRM1 protects neurons against β-amyloid peptide (Aβ) neurotoxicity through mTOR signaling.
METHODS: The effects of OPRM1 activation on Aβ oligomers-induced neurotoxicity were assessed by cell viability and neurite outgrowth assay in primary cultured cortical neurons. The activities of mTOR, protein kinase B (Akt) and p70 ribosomal S6 kinase (p70 S6k) upon OPRM1 activation by morphine were measured by immunoblotting their phosphorylation status.
RESULTS: Morphine dose-dependently attenuated Aβ oligomers-induced neurotoxicity. Aβ oligomers downregulated mTOR signaling. Morphine significantly rescued mTOR signaling by reversal of Aβ oligomers' effect on mTOR and its upstream signaling molecule Akt, as well as its downstream molecule p70 S6k. Moreover, the neuroprotective effect of morphine could be reversed by OPRM1 selective antagonist and phosphatidylinositol 3-kinases (PI3K), Akt and mTOR inhibitors. Furthermore, endogenous opioids-enkaphalins also attenuated Aβ oligomers-induced neurotoxicity.
CONCLUSIONS: Our findings demonstrated OPRM1 activation attenuated Aβ oligomers-induced neurotoxicity through mTOR signaling. It may provide new insight into the pathological process and useful strategy for therapeutic interventions against Aβ neurotoxicity.
© 2014 John Wiley & Sons Ltd.

Entities:  

Keywords:  Alzheimer's disease; Mechanistic/mammalian target of rapamycin; β-Amyloid peptide; μ-Opioid receptor

Mesh:

Substances:

Year:  2014        PMID: 25146548      PMCID: PMC6495561          DOI: 10.1111/cns.12316

Source DB:  PubMed          Journal:  CNS Neurosci Ther        ISSN: 1755-5930            Impact factor:   5.243


  14 in total

1.  Largazole is a Brain-Penetrant Class I HDAC Inhibitor with Extended Applicability to Glioblastoma and CNS Diseases.

Authors:  Fatma H Al-Awadhi; Lilibeth A Salvador-Reyes; Lobna A Elsadek; Ranjala Ratnayake; Qi-Yin Chen; Hendrik Luesch
Journal:  ACS Chem Neurosci       Date:  2020-06-19       Impact factor: 4.418

2.  Decreased Expression of Plasma MicroRNA in Patients with Methamphetamine (MA) Use Disorder.

Authors:  Yan Zhao; Kai Zhang; Haifeng Jiang; Jiang Du; Zong Na; Wei Hao; Shunying Yu; Min Zhao
Journal:  J Neuroimmune Pharmacol       Date:  2016-04-23       Impact factor: 4.147

3.  Aquaporin 4 Forms a Macromolecular Complex with Glutamate Transporter 1 and Mu Opioid Receptor in Astrocytes and Participates in Morphine Dependence.

Authors:  Hui Wang; Shiqi Wang; Kang Zhang; Hua Wang; Liting Lan; Xiaoyun Ma; Xiaoyan Liu; Shuzhuo Zhang; Jianquan Zheng; Xiaoli Wei; Haitao Yan
Journal:  J Mol Neurosci       Date:  2017-03-24       Impact factor: 3.444

Review 4.  Erythropoietin and mTOR: A "One-Two Punch" for Aging-Related Disorders Accompanied by Enhanced Life Expectancy.

Authors:  Kenneth Maiese
Journal:  Curr Neurovasc Res       Date:  2016       Impact factor: 1.990

Review 5.  Targeting molecules to medicine with mTOR, autophagy and neurodegenerative disorders.

Authors:  Kenneth Maiese
Journal:  Br J Clin Pharmacol       Date:  2015-12-26       Impact factor: 4.335

Review 6.  The mechanistic target of rapamycin (mTOR) and the silent mating-type information regulation 2 homolog 1 (SIRT1): oversight for neurodegenerative disorders.

Authors:  Kenneth Maiese
Journal:  Biochem Soc Trans       Date:  2018-03-09       Impact factor: 5.407

7.  Modulation of mTOR Activity by μ-Opioid Receptor is Dependent upon the Association of Receptor and FK506-Binding Protein 12.

Authors:  Yan Wang; Yan-Hui Ge; Yan-Xia Wang; Ting Liu; Ping-Yee Law; Horace H Loh; Hong-Zhuan Chen; Yu Qiu
Journal:  CNS Neurosci Ther       Date:  2015-07       Impact factor: 5.243

8.  The Molecular Mechanism of Glucagon-Like Peptide-1 Therapy in Alzheimer's Disease, Based on a Mechanistic Target of Rapamycin Pathway.

Authors:  Lin Li
Journal:  CNS Drugs       Date:  2017-07       Impact factor: 5.749

9.  Dysregulation of metabolic flexibility: The impact of mTOR on autophagy in neurodegenerative disease.

Authors:  Kenneth Maiese
Journal:  Int Rev Neurobiol       Date:  2020-08-11       Impact factor: 3.230

Review 10.  WISP1: Clinical insights for a proliferative and restorative member of the CCN family.

Authors:  Kenneth Maiese
Journal:  Curr Neurovasc Res       Date:  2014       Impact factor: 1.990

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.